Status:
UNKNOWN
Radial Versus Femoral Access for Superselective Embolization of Hepatocellular Carcinoma
Lead Sponsor:
Humanitas Clinical and Research Center
Conditions:
Hepatocellular Carcinoma
Hepatocellular Carcinoma Non-resectable
Eligibility:
All Genders
40-90 years
Phase:
NA
Brief Summary
The aim of this prospective, randomized study is to compare TRA vs TFA for superselective embolization of HCC using bland microparticles performed by multiple operators. In particular, main objective...
Detailed Description
Hepatic arterial chemoembolization is a safe, proven, and effective technique for the treatment of a number of malignancies, including primary and secondary tumors \[1, 2\]. This endovascular treatmen...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- patients affected by HCC with indication to TAE from a multidisciplinary team discussion.
- Exclusion criteria
- TAE for other malignancies or bleedings;
- Pregnancy.
Exclusion
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2020
Estimated Enrollment :
74 Patients enrolled
Trial Details
Trial ID
NCT03807947
Start Date
January 1 2019
End Date
April 1 2020
Last Update
January 17 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Humanitas Research Hospital
Rozzano, Lombardy, Italy, 20089